Search results for "regime"

showing 10 items of 750 documents

Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosph…

2019

Abstract Background Dose dense chemotherapy (DDT) has shown improvements of disease-free survival (DFS) and overall survival for primary breast cancer patients with a high risk of relapse. There are much less data about the effect of DDT in patients with intermediate risk of recurrence (1-3 positive axillary lymph nodes). Aim of this prospectively randomized trial was to investigate the superiority of a DDT schedule over a standard chemotherapy (ST) in primary breast cancer patients with 1-3 positive axillary lymph nodes. Methods The ASG1-3 study is a prospectively randomized, open label phase III study of the Adjuvant Study Group of the NOGGO association. Patients were eligible for the tri…

Cancer ResearchChemotherapymedicine.medical_specialtyeducation.field_of_studyAxillary lymph nodesDose-dense chemotherapybusiness.industrymedicine.medical_treatmentPopulationmedicine.diseaseGastroenterologyRegimenmedicine.anatomical_structureBreast cancerOncologyInternal medicinemedicineAdjuvant therapyeducationbusinessEpirubicinmedicine.drugCancer Research
researchProduct

External-beam radiotherapy as preparative regimen for hepatocyte transplantation after partial hepatectomy

2006

Purpose: The transplantation of donor hepatocytes is considered a promising option to correct chronic liver failure through repopulation of the diseased organ. This study describes a novel selective external-beam irradiation technique as a preparative regimen for hepatocyte transplantation. Methods and Materials: Livers of dipeptidylpeptidase IV (DPPIV)–deficient rats were preconditioned with external-beam single-dose irradiation (25 Gy) delivered to two thirds of the liver. Four days later, a one-third partial hepatectomy (PH) was performed to resect the untreated liver section, and 15 million wild-type (DPPIV + ) hepatocytes were transplanted via the spleen into the recipient livers. The …

Cancer ResearchPathologymedicine.medical_specialtyTransplantation ConditioningDipeptidyl Peptidase 4medicine.medical_treatmentSpleenmedicineAnimalsHepatectomyRadiology Nuclear Medicine and imagingExternal beam radiotherapyDipeptidyl peptidase-4Cell ProliferationPreparative RegimenRadiationbusiness.industryRats Inbred F344RatsTransplantationRadiation therapymedicine.anatomical_structureLiverOncologyHepatocyteChronic DiseaseHepatocytesFemaleHepatectomybusinessLiver FailureInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Fractionated External Beam Radiotherapy as a Suitable Preparative Regimen for Hepatocyte Transplantation After Partial Hepatectomy

2010

Purpose Hepatocyte transplantation is strongly considered to be a promising option to correct chronic liver failure through repopulation of the diseased organ. We already reported on extensive liver repopulation by hepatocytes transplanted into rats preconditioned with 25-Gy single dose selective external beam irradiation (IR). Herein, we tested lower radiation doses and fractionated protocols, which would be applicable in clinical use. Methods and Material Livers of dipeptidylpeptidase IV (DPPIV)-deficient rats were preconditioned with partial liver external beam single dose IR at 25 Gy, 8 Gy, or 5 Gy, or fractionated IR at 5 × 5 Gy or 5 × 2 Gy. Four days after completion of IR, a partial …

Cancer ResearchTransplantation ConditioningDipeptidyl Peptidase 4medicine.medical_treatmentmedicineAnimalsHepatectomyRadiology Nuclear Medicine and imagingExternal beam radiotherapyPreparative RegimenRadiationbusiness.industryDose fractionationRatsRadiation therapyTransplantationmedicine.anatomical_structureLiverOncologyHepatocyteHepatocytesDose Fractionation RadiationTransplantation ConditioningHepatectomyNuclear medicinebusinessBiomarkersInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Dou…

2021

BackgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) are available.MethodsThis multicenter, retrospective study aimed at evaluating clinicians’ attitude, and the safety and effectiveness of post-induction strategies in consecutive patients affected by left-sided RAS/BRAF wild-type mCRC treated with doublet chemotherapy plus anti-EGFR as first-line regimen, who did not experience disease progression within 6 months from induction initiation, at 21 Italian and 1 Spanish Institutions. The measured clinical outcomes were: p…

Cancer Researchmedicine.medical_specialtyColorectal cancerPopulationGastroenterologymaintenanceFOLFIRIFOLFOXInternal medicinecetuximabmedicineAdverse effecteducationRC254-282education.field_of_studybusiness.industryMCRCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studymedicine.diseaseRegimenFOLFOXOncologyCohortFOLFIRIbusinesspanitumumabmedicine.drugFrontiers in Oncology
researchProduct

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

1991

A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i. v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1–3; and vindesine, 3 mg/m2 given i.v. on day 1; treatment repeated every 3 weeks). In 64 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.

Cancer Researchmedicine.medical_specialtyLung NeoplasmsTime FactorsVindesinemedicine.medical_treatmentMitomycinPhases of clinical researchToxicologyGastroenterologyInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerEtoposideEtoposideNeoplasm StagingPharmacologyChemotherapybusiness.industryMitomycin CRemission InductionCombination chemotherapymedicine.diseaseSurgeryRegimenOncologyLymphatic MetastasisVindesineDrug Evaluationbusinessmedicine.drugCancer chemotherapy and pharmacology
researchProduct

Treatment of Stage III-IV Non-Small-Cell Lung Carcinoma with Vinorelbine in Combination with Ifosfamide plus MESNA: A Study by the Southern Italy Onc…

1996

Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were se…

Cancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentVinblastineVinorelbineGastroenterologyCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideLung cancerAgedMesnaMesnaChemotherapyLeukopeniaIfosfamidePerformance statusbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurgeryRegimenOncologymedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

68 O - Maintenance low-dose (LD) oral idarubicin (oIDA) in elderly patients (pts) with acute myelogeneous leukemia (AML)

1996

IDA by i.v. route. especially in combination with cytosine arabinoside (Ara-C). proved quite effective for intensive chemotherapy of AML However, persisting controversies on aggressive/intensive versus “ottenvated” regimens for elderly AML pts emphasize the interest of olDA in this latter setting (ct M.R. Howard et al and M.J. Keating. Clin. Drug Invest. 1995; 9. Suppl. 2: 16–38) A 69% complete response (CR) rate was recentty reported (F. Leoni et al Br. J. Hoematol 1995; 90: 169–174) among 25 elderly AML pts (> 60 yrs old) with an “attenuated” dose of IDA, i.e. 8 mg/m2 i.v. d, 1. 3, and 5. plus Ara-C 200 mg/m2 by continuous i.v. infusion (ClV) d, 1–7, and etoposide (VP-16) 60 mg/m2 i.v. d,…

Cancer Researchmedicine.medical_specialtyNauseabusiness.industryInduction chemotherapymedicine.diseaseGastroenterologyMinimal residual diseaseSurgeryRegimenOncologyOral administrationInternal medicinemedicineMucositisIdarubicinmedicine.symptombusinessEtoposidemedicine.drugEuropean Journal of Cancer
researchProduct

A randomized phase II study of estramustine phosphate versus estramustine phosphate plus etoposide in hormone refractory prostate cancer (HRPC)

2008

20632 Background: Docetaxel-based regimens represent the treatment of choice of HRPC. However, in some patients toxicity may be a concern and the quality of life may be compromised. The aim of this phase II randomized study is to investigate the efficacy and safety of low-dose chemotherapy regimen adopting a combination of EMP and VP16 in patients affected by HRPC. Methods: 54 HRPC patients were randomized between: arm A, daily oral standard dose EMP (10mg/kg) and arm B, low-dose EMP (3mg/kg) plus VP16 (25mg/mq) for 2 weeks followed by 2-weeks’rest. Systemic toxicity and hematologic exams were monitored every 2 weeks. Performance status, pain and analgesic use were evaluated according to WH…

Cancer Researchmedicine.medical_specialtyPerformance statusbusiness.industryUrologyprostate cancer chemotherapy efficacyPhases of clinical researchChemotherapy regimenlaw.inventionOncologyDocetaxelRandomized controlled triallawAnesthesiaToxicitymedicinebusinessAdverse effectEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct

Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukem…

2010

Abstract 207 Introduction: Chemoimmunotherapy regimens have become the treatment standard for patients with CLL. Ofatumumab is a human monoclonal antibody that targets a unique small-loop epitope on CD20 and elicits rapid and efficient in vitro complement-dependent cytotoxicity, as well as antibody-dependent cellular cytotoxicity. Recent studies demonstrated single-agent ofatumumab activity, with high overall response rates (ORR) in patients with refractory CLL. We conducted an international, randomized, parallel group, Phase II trial with two doses of ofatumumab combined with fludarabine and cyclophosphamide (FC) in previously untreated patients with CLL to evaluate the efficacy and tolera…

Cancer Researchmedicine.medical_specialtybusiness.industryMedizinHematologyNeutropeniamedicine.diseaseOfatumumabFludarabineRegimenchemistry.chemical_compoundOncologyTolerabilitychemistryChemoimmunotherapyInternal medicineImmunologymedicineRituximabbusinessFebrile neutropeniamedicine.drugClinical Lymphoma Myeloma and Leukemia
researchProduct

Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

2021

ObjectiveRadiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies.Materials and Method…

Cancer Researchmedicine.medical_specialtyelderly oncologymedicine.medical_treatmentelderlyEffective dose (radiation)medicinegeriatric oncologyRC254-282radiotherapyPerformance statushypofractionationbusiness.industryHead and neck cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRadiation therapyRegimenSystematic reviewOncologyGeriatric oncologyConcomitanthead and neck cancerSystematic ReviewRadiologybusinessFrontiers in Oncology
researchProduct